Placebo Oral Tablet + Alvelestat oral tablet - dose 1 + Alvelestat oral tablet - dose 2
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Trial Timeline
Oct 29, 2018 → Mar 30, 2022
NCT ID
NCT03636347About Placebo Oral Tablet + Alvelestat oral tablet - dose 1 + Alvelestat oral tablet - dose 2
Placebo Oral Tablet + Alvelestat oral tablet - dose 1 + Alvelestat oral tablet - dose 2 is a phase 2 stage product being developed by Mereo BioPharma for Alpha 1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03636347. Target conditions include Alpha 1-Antitrypsin Deficiency, Emphysema, COPD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03636347 | Phase 2 | Completed |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency